CN110358782A - A kind of polygenes recombination Lactobacillus casei, preparation method and application - Google Patents
A kind of polygenes recombination Lactobacillus casei, preparation method and application Download PDFInfo
- Publication number
- CN110358782A CN110358782A CN201910668557.5A CN201910668557A CN110358782A CN 110358782 A CN110358782 A CN 110358782A CN 201910668557 A CN201910668557 A CN 201910668557A CN 110358782 A CN110358782 A CN 110358782A
- Authority
- CN
- China
- Prior art keywords
- gtxa
- primer
- seq
- flfa
- pmd18
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000199866 Lactobacillus casei Species 0.000 title claims abstract description 39
- 235000013958 Lactobacillus casei Nutrition 0.000 title claims abstract description 38
- 229940017800 lactobacillus casei Drugs 0.000 title claims abstract description 38
- 230000006798 recombination Effects 0.000 title claims abstract description 24
- 238000005215 recombination Methods 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000013612 plasmid Substances 0.000 claims abstract description 69
- 238000012408 PCR amplification Methods 0.000 claims abstract description 35
- 239000012634 fragment Substances 0.000 claims abstract description 34
- 238000005516 engineering process Methods 0.000 claims abstract description 5
- 230000003321 amplification Effects 0.000 claims description 39
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 38
- 238000011144 upstream manufacturing Methods 0.000 claims description 28
- 241000606562 Gallibacterium anatis Species 0.000 claims description 25
- 239000003292 glue Substances 0.000 claims description 19
- 241000588724 Escherichia coli Species 0.000 claims description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 14
- 230000004927 fusion Effects 0.000 claims description 13
- 238000004064 recycling Methods 0.000 claims description 13
- 238000013461 design Methods 0.000 claims description 11
- 230000002068 genetic effect Effects 0.000 claims description 11
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 235000013351 cheese Nutrition 0.000 claims description 7
- 235000014655 lactic acid Nutrition 0.000 claims description 7
- 239000004310 lactic acid Substances 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000002299 complementary DNA Substances 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 230000004087 circulation Effects 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 21
- 108090000623 proteins and genes Proteins 0.000 abstract description 20
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract description 4
- 102000057593 human F8 Human genes 0.000 abstract description 4
- 229940047431 recombinate Drugs 0.000 abstract description 4
- 239000013598 vector Substances 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 32
- 241000894006 Bacteria Species 0.000 description 25
- 241000711450 Infectious bronchitis virus Species 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 18
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 11
- 238000000246 agarose gel electrophoresis Methods 0.000 description 9
- 239000003550 marker Substances 0.000 description 8
- 241000287828 Gallus gallus Species 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229960003276 erythromycin Drugs 0.000 description 6
- 238000012797 qualification Methods 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 206010011732 Cyst Diseases 0.000 description 5
- 208000031513 cyst Diseases 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 210000003101 oviduct Anatomy 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 101150027674 S1 gene Proteins 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241000272525 Anas platyrhynchos Species 0.000 description 3
- 208000007893 Salpingitis Diseases 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 241001558036 Gallibacterium anatis UMN179 Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 241001056488 Anatis Species 0.000 description 1
- 241000726103 Atta Species 0.000 description 1
- 241000886677 Duck adenovirus 1 Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 101710175243 Major antigen Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000009361 aviculture Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000003990 capacitor Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of polygenes to recombinate Lactobacillus casei, preparation method and application, it is cloned by T-A and target gene is connected into pMD18-T respectively, conversion to DH5 α competent cell obtains pMD18-T-S1, pMD18-T-GtxA-N and pMD18-T-flfA, respectively with pMD18-T-S1, pMD18-T-GtxA-N and pMD18-T-flfA is that template is expanded, obtain three target fragments, three target fragments are connected as a bar segment, PCR amplification pMG36e is so that it becomes linearized vector, the segment is connected with linearized vector by seamless clone technology, and connection product is converted and obtains recombinant plasmid into XL1-Bule competent cell, its electrotransformation is entered Recombination Lactobacillus casei is obtained in Lactobacillus casei.
Description
Technical field
The invention belongs to microorganisms technical field, in particular to a kind of polygenes recombinates Lactobacillus casei, preparation method
And application.
Background technique
Laying hen cyst of fallopian tube is always the important epidemic disease for endangering aviculture, and the disease is with caseous salpingitis, fallopian tubal
Blocking is characterized, and often leads to the chicken egg productivity of egg-laying peak and quality of laying eggs declines rapidly, especially the high yield of current year life
Hen is more common.Have been generally acknowledged that infectious bronchitis virus, duck source chicken bacillus (G.anatis), Egg Drop syndrome virus and clothing
Substance etc. is to cause salpingitis and cyst of fallopian tube main pathogens, especially G.anatis.RTX toxin (Repeats in
Toxin) it is present in a variety of Gram-negative bacterias, plays an important role in the pathogenic course to specific species, GtxA albumen
It is duck source chicken bacillus RTX sample toxin, there is leucocytotoxicity and hemolytic activity, research shows that the N-terminal region of GtxA albumen has
Good immunogenicity, and prove that recombinant protein GtxA-N can trigger effective immunoprotection and can be used as anti-G.anatis's processed
Vaccine antigen.F17 sample pili is the important virulence factor of G.anatis, and can be used as that non-serotype relies on it is conservative potential
Vaccine candidate albumen.The main infringement chicken respiratory system of IBV virus and digestion reproductive system, and it is believed that chicken salpingo tumour
Generation it is related with chicken IBV virus early infection, meanwhile, tend to isolate IBV virus in the chicken body of G.anatis infection, subtract
Egg syndrome virus and mycoplasma etc., therefore, IBV virus are also the important pathogen for causing laying hen cyst of fallopian tube.IBV virus base
4 kinds of structural proteins are encoded altogether because organizing, and wherein prominent (S) albumen of the fibre on outer virionic membrane needs 2 that are cracked into S1 and S2 upon translation
Protein protomer could become the maturation protein for having biological activity, and Sl albumen is the major antigen of IBV virus.
Currently, G.anatis and IBV have been in global distribution, and it can cause defeated ovum after infecting laying hen researches show that the two
Guan Yan and cyst of fallopian tube, therefore, to both disease Synthetical prevention can largely reduce laying hen cyst of fallopian tube and
The economic loss of laying hen industry is effectively reduced in the generation of salpingitis.Vaccine immunity is the important means of prevention and control epidemic disease, develops peace
Entirely, G.anatis and IBV combined vaccine efficiently, practical seems promising important.The selection of vaccine is in entire immunoprotection process
In it is extremely important, be the important approach of infection through mucous membrane intrusion host, therefore disease can effectively be resisted by mucosa-immune
The intrusion of substance.
Body mucosal immune system can be stimulated to generate local specific immune response for this reason, it may be necessary to develop one kind, to draw
The vaccine of systemic immunity reaction is played, immunoprotection thus is carried out to poultry.
Summary of the invention
The purpose of the present invention is to provide one kind can prepare safe and efficient, practical G.anatis and IBV combined vaccine
Polygenes recombinates Lactobacillus casei.
A kind of polygenes provided by the invention recombinates Lactobacillus casei, by recombinant plasmid pMG36e-S1-GtxA-flfA
Electrotransformation to cheese lactic acid competent cell bacillus obtains;The polygenes recombination Lactobacillus casei is by recombinant plasmid
PMG36e-S1-GtxA-flfA electrotransformation to cheese lactic acid competent cell bacillus obtains;The recombinant plasmid pMG36e-S1-
GtxA-flfA is to be connected into fusion S1-GtxA-flfA between the site kPnI of linear plasmid pMG36e and the site SalI to obtain
It arrives, the nucleotide sequence of the fusion S1-GtxA-flfA is as shown in SEQ ID NO.19.
Further, the Lactobacillus casei is Lb.casei CECT5276.
The present invention also provides the preparation methods of above-mentioned polygenes recombination Lactobacillus casei, include the following steps:
S1 designs specificity amplification primer 1, such as sequence table of upstream and downstream primer using IBV Jin-13 virus cDNA as template
Shown in SEQ ID NO:1 and SEQ ID NO:2, carries out PCR amplification and obtain IBV virus S1 genetic fragment;Amplified fragments are recycled through glue
It is attached afterwards with pMD18-T carrier, connection product is converted to bacillus coli DH 5 alpha competent cell, and carry out positive colony
The identification of screening and recombination positive plasmid, obtains recombinant plasmid pMD18-T-S1;
Using G.anatis UMN179 full-length genome as template, specificity amplification primer 2, upstream and downstream primer such as sequence are designed
Shown in table SEQ ID NO:3 and SEQ ID NO:4, carries out PCR amplification and obtain G.anatisGtxA genetic fragment;Amplified fragments are through glue
It is attached after recycling with pMD18-T carrier, connection product is converted to bacillus coli DH 5 alpha competent cell, and carry out the positive
The identification of colony screening and recombination positive plasmid, obtains recombinant plasmid pMD18-T-GtxA;
Using G.anatis full-length genome as template, specificity amplification primer 3, upstream and downstream primer such as sequence table SEQ are designed
Shown in ID NO:5 and SEQ ID NO:6, carries out PCR amplification and obtain G.anatis flfA genetic fragment, amplified fragments are recycled through glue
It is attached afterwards with pMD18-T carrier, connection product is converted to bacillus coli DH 5 alpha competent cell, and carry out positive colony
The identification of screening and recombination positive plasmid, obtains recombinant plasmid pMD18-T-flfA.
S2 designs specificity amplification primer 4, such as sequence table of upstream and downstream primer with recombinant plasmid pMD18-T-S1 template
Shown in SEQ ID NO:7 and SEQ ID NO:8, PCR amplification is carried out, identified result correctly carries out glue recycling afterwards, obtains purpose
Segment 1;
With recombinant plasmid pMD18-T-GtxA template, specificity amplification primer 5, upstream and downstream primer such as sequence table SEQ are designed
Shown in ID NO:9 and SEQ ID NO:10, PCR amplification is carried out, it is identified, glue recycling is carried out after as a result correct, obtains purpose piece
Section 2;
With recombinant plasmid pMD18-T-flf template, specificity amplification primer 6, upstream and downstream primer such as sequence table SEQ are designed
Shown in ID NO:11 and SEQ ID NO:12, PCR amplification is carried out, identified result correctly carries out glue recycling afterwards, obtains purpose piece
Section 3;
S3 is once expanded target fragment 1, target fragment 2 and target fragment 3 by overlapping PCR method, one
It is secondary amplification terminate after into PCR system be added specificity amplification primer 7, upstream and downstream primer such as sequence table SEQ ID NO:13 and
Shown in SEQ ID NO:14, secondary amplification is carried out, correct amplified production recycling will be identified, obtains fusion S1-GtxA-
flfA;
S4 designs specificity amplification primer 8, upstream and downstream primer such as sequence table SEQ ID using pMG36e plasmid as template
Shown in NO:15 and SEQ ID NO:16, PCR amplification is carried out, obtains linear plasmid pMG36e;
Fusion S1-GtxA-flfA and linear plasmid pMG36e are attached by S5 by seamless clone technology, will
Connection product is converted to Escherichia coli XL1-Bule competent cell, obtains recombinant plasmid pMG36e-S1-GtxA-flfA;
S6 mixes recombinant plasmid pMG36e-S1-GtxA-flfA with Lactobacillus casei competent cell, ice bath
5min, then high-voltage pulse electric shock converts, much genetic recombination Lactobacillus casei.
Further, the preparation method of above-mentioned polygenes recombination Lactobacillus casei, in S1, PCR system are as follows: 2 × Easy
Taq Super PCR Master Mix 25ul, upstream primer 1ul, downstream primer 1ul, template DNA 21ul;
PCR program are as follows:
95 DEG C, 5min;
30 circulations:
95 DEG C, 30s,
56 DEG C, 30s,
72 DEG C, primer 1 expands 60s/ primer 2 amplification 90s/ primer 3 and expands 30s;
72℃,10min。
Compared with prior art, beneficial effects of the present invention: the present invention successfully constructs one plant of coexpression IBV-S1 and Ya Yuan
Chicken bacillus FlfA, gtxA recombinate Lactobacillus casei, are a kind of mucous membrane microorganisms in conjunction with duck source chicken bacillus, are mainly colonized in and exhale
Road, alimentary canal and urogenital system this feature are inhaled, in preparation for the live vector epidemic disease of coexpression S1-GtxA-FlfA albumen
Select lactic acid bacteria as the carrier of present antigen when seedling, it is not only safe and non-toxic in this way, but also body intestinal mucosa can be induced to produce
Raw immune response, irritating body generates whole body specific immune response, to play a protective role.
Detailed description of the invention
Fig. 1 is PCR amplification result figure (the M:DNA Marker 250Ladder of 1 three kinds of genes of the embodiment of the present invention;1:
The PCR product of IBV S1 gene;2:G.anatis GtxA gene PCR product;3:G.anatis flfA gene PCR product).
The PCR that Fig. 2 is 1 recombinant plasmid pMD18-T-S1 of the embodiment of the present invention identifies (M:DNA Marker250Ladder;
The PCR product of 1:IBV S1 gene;2: plasmid pMD18-T-S1).
The PCR that Fig. 3 is 1 recombinant plasmid pMD18-T-GtxA of the embodiment of the present invention identifies (M:DNA Marker
250Ladder;The PCR product of 1:G.anatis GtxA gene;2: plasmid pMD18-T-GtxA).
Fig. 4 is the PCR identification of M of 1 recombinant plasmid pMD18-T-GtxA of the embodiment of the present invention: DNA Marker
250Ladder;The PCR product of 1:G.anatis flfA gene;2: plasmid pMD18-T-flfA).
Fig. 5 is PCR amplification result (the M:DNA Marker DL2000 of 1 target fragment of the embodiment of the present invention;1:IBV S1
The PCR product of gene;2:G.anatis GtxA gene PCR product;3:G.anatis flfA).
Fig. 6 is concatenated target gene over-lap PCR amplification (the M:DNA Marker DL of the embodiment of the present invention 1
15000;1: fusion segment S1-GtxA-flfA).
Fig. 7 is PCR amplification result (the M:DNA Marker DL15000 of 1 plasmid pMG36e of the embodiment of the present invention;1: plasmid
pMG36e)。
Fig. 8 is PCR amplification result (M: the λ-Hind of 1 recombinant plasmid pMG36e-S1-GtxA-flfA of the embodiment of the present invention
III digest DNA Marker;1-4: recombinant plasmid pMG36e-S1-GtxA-flfA).
Fig. 9 is identification (the M:DNA Marker DL 15000 of 2 recombinant bacterium of the embodiment of the present invention;1-5:L.casei 5276
In plasmid recombinant plasmid pMG36e-S1-GtxA-flfA;6: negative control).
Figure 10 is the growth curve of the recombinant bacterium of the embodiment of the present invention 3.
Figure 11 is that the external genetic stability of recombination Lactobacillus casei of the embodiment of the present invention 4 analyzes result (M:DNA
Mareker 250Ladder;PCR product of the 1-10:S1-GtxA-flfA gene in 1-20 generation recombination Lactobacillus casei;11:
Negative control)
Specific embodiment
With reference to the accompanying drawing and the specific embodiment of the present invention is described in detail in specific embodiment, but answers
When understanding that the protection scope of the present invention is not limited by the specific implementation manner, operating process of the present invention is such as without special theory
Bright is conventional method, and being related to reagent is to be commercially available on the market.
IBVJin-13 virus used in the present invention is recorded in " " Agricultural University Of Anhui's journal " 01 phase in 2012, paper name
Claim " Jin13 plants of avian infectious bronchitis virus of separation and identification " " in, applicant's guarantee is from applying for mesh to public affairs in 20 years
Crowd provides biomaterial.
Embodiment 1
Polygenes of the invention recombinates Lactobacillus casei, extremely by recombinant plasmid pMG36e-S1-GtxA-flfA electrotransformation
Cheese lactic acid competent cell bacillus obtains;The recombinant plasmid pMG36e-S1-GtxA-flfA is by fusion S1-
GtxA-flfA is connected between the site kPnI of linear plasmid pMG36e and the site SalI, the fusion S1-GtxA-flfA
Nucleotide sequence as shown in SEQ ID NO.19.
A kind of preparation method of polygenes recombination Lactobacillus casei, its step are as follows:
According to GenBank IBV Jin-13 virus S1 gene, GtxA, flfA gene of G.anatis UMN179 and shuttle
Expression vector pMG36e sequence, using primer-design software Premier 5.0 design multipair specific primer for construct recombination
Plasmid pMG36e-S1/GtxA/flfA, primer are synthesized by giving birth to work bioengineering (Zhengzhou) Co., Ltd.
S1 designs specificity amplification primer 1, such as sequence table of upstream and downstream primer using IBV Jin-13 virus cDNA as template
Shown in SEQ ID NO:1 and SEQ ID NO:2, carries out PCR amplification and obtain IBV virus S1 genetic fragment;Amplified fragments are recycled through glue
It is attached afterwards with pMD18-T carrier, connection product is converted to bacillus coli DH 5 alpha competent cell, and carry out positive colony
The identification of screening and recombination positive plasmid, obtains recombinant plasmid pMD18-T-S1;
Using G.anatis full-length genome as template, specificity amplification primer 2, upstream and downstream primer such as sequence table SEQ are designed
Shown in ID NO:3 and SEQ ID NO:4, carries out PCR amplification and obtain G.anatis GtxA genetic fragment;Amplified fragments are recycled through glue
It is attached afterwards with pMD18-T carrier, connection product is converted to bacillus coli DH 5 alpha competent cell, and carry out positive colony
The identification of screening and recombination positive plasmid, obtains recombinant plasmid pMD18-T-GtxA;
Using G.anatis full-length genome as template, specificity amplification primer 3, upstream and downstream primer such as sequence table SEQ are designed
Shown in ID NO:5 and SEQ ID NO:6, carries out PCR amplification and obtain G.anatis flfA genetic fragment, obtain recombinant plasmid
pMD18-T-flfA。
The system and amplification program that three PCR react in S1 are as shown in table 1,2:
The PCR reaction system of 1 S1 of table
2 PCR amplification program of table
Pcr amplification product in 1%TAE agarose gel electrophoresis identify, as a result as shown in Figure 1 (M:DNAMarker
250Ladder;The PCR product of 1:IBV S1 gene;2:G.anatis GtxA gene PCR product;G.anatis flfA gene
PCR product), and according to DNA gel electrophoresis kit specification, purification and recovery specific band.
Three glue recovery product fS1 genes, GtxA gene and flfA gene, then connect with carrier T respectively in S1, connection
System such as table 3:
3 linked system of table
Three linked system mixtures are placed in 16 DEG C of link slot and carry out staying overnight connection, then by three connection products
It is converted respectively to bacillus coli DH 5 alpha competent cell, specific steps are as follows:
(1) 10 μ L connection products and 100 μ L bacillus coli DH 5 alphas are mixed by state cell, ice bath 30min;
(2) in 42 DEG C of water-bath heat shock 90s, ice bath 5min in mixture of ice and water is moved to;
(3) the LB culture medium of 1mL, 200r/min, 37 DEG C of culture 1h are added into EP pipe;
(4) bacterium solution 10000rpm, 4 DEG C of centrifugation 5min after cultivating use remaining bacterium solution in EP pipe after abandoning 900 μ L supernatants
Liquid-transfering gun mixing takes appropriate bacterium solution to be coated in the LB solid medium containing 100 μ g/mL Amp, and 37 DEG C of stationary cultures are stayed overnight, then
Carry out positive colony screening.
The recombination positive plasmid identification system of three connection products is essentially identical, and difference is primer difference, corresponding to draw
Object is respectively primer 1, primer 2 and primer 3, it is specific as shown in table 4:
4 recombinant plasmid PCR identification system of table
PCR amplification condition is identified in 1%TAE agarose gel electrophoresis with its amplified production of table 2, is expanded by PCR
Increasing and identify, obtains correct target fragment, qualification result is as shown in Figure 2,3, 4, position size respectively about 1608bp,
2847bp, 549bp, sequencing result are correct.
S2 designs specificity amplification primer 4, such as sequence table of upstream and downstream primer with recombinant plasmid pMD18-T-S1 template
Shown in SEQ ID NO:7 and SEQ ID NO:8, PCR amplification is carried out, identified result correctly carries out glue recycling afterwards, obtains purpose
Segment 1;
With recombinant plasmid pMD18-T-GtxA template, specificity amplification primer 5, upstream and downstream primer such as sequence table SEQ are designed
Shown in ID NO:9 and SEQ ID NO:10, PCR amplification is carried out, it is identified, glue recycling is carried out after as a result correct, obtains purpose piece
Section 2;
With recombinant plasmid pMD18-T-flf template, specificity amplification primer 6, upstream and downstream primer such as sequence table SEQ are designed
Shown in ID NO:11 and SEQ ID NO:12, PCR amplification is carried out, identified result correctly carries out glue recycling afterwards, obtains purpose piece
Section 3;
Three PCR amplification systems are essentially identical in S2, and difference is primer difference, and primer is respectively primer 4,5 and of primer
Primer 6, PCR reaction system such as table 5:
The PCR reaction system of 5 S2 of table
Each pcr amplification product is identified that qualification result is as schemed by amplification condition in 1%TAE agarose gel electrophoresis
Correct through sequencing result shown in 5, phenomena such as mispairing does not occur for base sequence, carries out glue after as a result correct and recycles target fragment ,-
20 DEG C save backup.
S3 is once expanded target fragment 1, target fragment 2 and target fragment 3 by overlapping PCR method, one
Specificity amplification primer 7, each 2uL of upstream and downstream primer, upstream and downstream primer such as sequence are added into PCR system after terminating for secondary amplification
Shown in table SEQ ID NO:13 and SEQ ID NO:14, secondary amplification is carried out, correct amplified production recycling will be identified, is melted
Close gene S1-GtxA-flfA;
The reaction system and reaction condition once expanded such as table 6,7:
Table amplification reaction system of 6 over-lap PCR
Table amplification condition of 7 over-lap PCR
The reaction condition of secondary amplification such as table 8:
Table amplification condition of 8 over-lap PCR
It is identified through 1%TAE agarose gel electrophoresis, qualification result at about 5052bp as shown in fig. 6, there is a specificity
Purpose band, it is consistent with expected results to pass through, PCR product purification kit recycle -20 DEG C save backup.
S4 designs specificity amplification primer 8, upstream and downstream primer such as sequence table SEQ ID using pMG36e plasmid as template
Shown in NO:15 and SEQ ID NO:16, PCR amplification is carried out, obtains linear plasmid pMG36e;
PCR reaction system and reaction condition such as table 9,10:
The PCR reaction system of the amplification of table 9 plasmid pMG36e
10 PCR amplification condition of table
It is identified through 1%TAE agarose gel electrophoresis, qualification result is as shown in fig. 7, obtain the specific item of about 3600bp
Band, as a result correctly.
It after 1 μ L DpnI enzymic digestion is added into PCR product, is recycled using PCR product purification kit, -20 DEG C of guarantors
It deposits spare.
Fusion S1-GtxA-flfA and linear plasmid pMG36e are attached by seamless clone technology, are obtained by S5
To recombinant plasmid pMG36e-S1-GtxA-flfA;Reaction system and response procedures such as table 11,12:
The seamless cloning reaction system of table 11
12 PCR amplification condition of table
After the identification of 1%TAE agarose gel electrophoresis, -20 DEG C are recycled through PCR product purification kit and is saved backup.
Seamless cloned sequence is gone into Escherichia coli XLI-Blue competent cell, operating procedure is as follows:
(1) 10 μ L connection products and 100 μ L Escherichia coli XLI-Blue competent cells are mixed, ice bath 30min;
(2) in 42 DEG C of water-bath heat shock 90s, ice bath 5min in mixture of ice and water is moved to;
(3) the LB culture medium of 1mL, 200r/min, 37 DEG C of culture 1h are added into EP pipe;
(4) bacterium solution 10000rpm, 4 DEG C of centrifugation 5min after cultivating use remaining bacterium solution in EP pipe after abandoning 900 μ L supernatants
Liquid-transfering gun mixing takes appropriate bacterium solution to be coated in the LB solid medium containing 100 μ g/mL Amp, and 37 DEG C of stationary cultures are stayed overnight, then
Carry out positive colony screening.
The step of positive colony screens are as follows: the single bacterium of the doubtful positive recombinant plasmid of picking is fallen within containing final concentration of 300 μ g/mL
In the MRS culture medium of erythromycin, 37 DEG C of stationary cultures for 24 hours after, design specificity amplification primer 6, such as sequence table of upstream and downstream primer
SEQ ID NO:17 and SEQ ID NO:18 carries out PCR identification, PCR identification system and reaction condition such as table 13,14:
13 recombinant plasmid pMG36e-S1-GtxA-flfA PCR identification system of table
14 PCR amplification condition of table
PCR product is identified in 1%TAE agarose gel electrophoresis, qualification result is as shown in figure 8, obtain about
5376bp purpose band, through being sequenced, as a result correctly.
S6 mixes recombinant plasmid pMG36e-S1-GtxA-flfA with Lactobacillus casei competent cell, ice bath
5min, then high-voltage pulse electric shock converts, much genetic recombination Lactobacillus casei.
Wherein, the preparation of Lactobacillus casei competent cell includes the following steps:
Lactobacillus casei (Lb.casei CECT5276) strain that -80 DEG C are saved, the MRS for lining non-resistant are solid
On body culture medium, 37 DEG C are stood for 24 hours, and picking single bacterium is fallen in the MRS culture medium of 5mL non-resistant, 37 DEG C of standing 18h;Take 2mL bacterium
Liquid is in 100mLMRS culture medium, 37 DEG C of cultures to OD600It is 0.3~0.5.After collecting thallus ice bath 5min, 4 DEG C,
10000rpm is centrifuged 15min, abandons supernatant, and 10% glycerol washing thalline being pre-chilled in equal volume is added, and washes repeatedly 3 times, is added
1mL is pre-chilled 10% glycerol and is resuspended.100 μ L of the competent cell prepared is taken to be sub-packed in 1.5mLEP pipe, -80 DEG C save backup.
The step of electrotransformation are as follows:
Taking 10 μ L concentration is the matter recombinant plasmid pMG36e-S1-GtxA-flfA of 1 μ g/mL, with the above-mentioned cheese prepared
For Bacillus acidi lactici by being mixed in state cell EP pipe (plasmid solution volume is no more than competence solution 1:10), ice bath 5min will
Mixed liquor is added in the sterile 2mm electricity revolving cup of pre-cooling, high-voltage pulse electric shock conversion.Conversion condition: electric field strength 2000V,
200 Ω of resistance, 25 μ F of capacitor.The SMRS fluid nutrient medium of 890 μ L is added in electric shock into electric revolving cup after finishing, moved after mixing
Into sterile EP tube, 37 DEG C of standing 3h.4 DEG C, 10000rpm, it is centrifuged 15min, 800 μ L supernatants are discarded, by remaining liq and bacterium
Body mixes, and is coated in the MRS solid medium containing 5 μ g/mL erythromycin, and observation as a result, use simultaneously after 37 DEG C of stationary culture 48h
PMG36e empty carrier conversion Lactobacillus casei compares.Doubtful recombinant lactic acid bacteria clone on picking plate, is connected to 5mL containing 5 μ
In the MRS culture medium of g/mL erythromycin, 37 DEG C of stationary culture 48h.
Embodiment 2
Recombinate the identification of Lactobacillus casei
Picking positive single bacterium is fallen in the MRS solid medium containing final concentration of 5 μ g/mL erythromycin, and 37 DEG C stand overnight
Culture, and PCR identification is carried out to bacterium solution.PCR identification system and reaction condition such as table 15,16:
Table 15 recombinates Lactobacillus casei PCR identification system
PCR amplification condition identifies in 1%TAE agarose gel electrophoresis with table 14, by PCR product, qualification result
As shown in figure 9, obtaining the purpose band of about 5376bp, position is correct.
Embodiment 3
Recombinate the growth conditions analysis of Lactobacillus casei
Recombinant bacterium is activated respectively with corresponding empty bacterium, recombinant bacterium is connected to the MRS containing 5mL containing 5 μ g/mL erythromycin and trains
It supports in base, empty bacterium is connected in non-resistant MRS culture medium, after 37 DEG C stand for 24 hours, then takes 1mL bacterium solution in being connected to 100mL MRS respectively
In culture medium, use MRS culture medium as blank control;37 DEG C of stationary cultures sample every 2h since 0h, measure culture solution
OD600Value continuously detects 14h, draws growth curve.The results are shown in Figure 10, the recombination cheese lactic acid bar speed of growth and empty cheese
Bacillus acidi lactici is compared, and without significant difference between them, the insertion of illustration purpose gene has no influence to host strain.
Embodiment 4
Genetic stability analysis of the target gene in recombination Lactobacillus casei
It chooses recombinant bacterium single bacterium to fall in MRS culture medium of the 5mL containing 1 μ g/mL erythromycin, 37 DEG C of standings are trained under conditions of for 24 hours
It supported for 20 generations, extracts bacterial genomes every a generation, for No. 9 specific primers to PCR identification is carried out, reaction system and reaction condition are same
2.6.3, PCR product is observed in 1%TAE agarose gel electrophoresis as a result, result is as shown in figure 11, in each generation recombinant bacterium
The purpose band of length about 5376bp can be amplified, it was demonstrated that fusion S1-GtxA-flfA can stablize in Lactobacillus casei
Heredity.
It should be noted that the step method used in claims of the present invention is same as the previously described embodiments, in order to anti-
It only repeats, description of the invention preferred embodiment, once a person skilled in the art knows basic creative general
It reads, then additional changes and modifications can be made to these embodiments.So it includes preferred real that the following claims are intended to be interpreted as
It applies example and falls into all change and modification of the scope of the invention.
Obviously, various changes and modifications can be made to the invention without departing from essence of the invention by those skilled in the art
Mind and range.In this way, if these modifications and changes of the present invention belongs to the range of the claims in the present invention and its equivalent technologies
Within, then the present invention is also intended to include these modifications and variations.
Sequence table
<110>Agricultural University Of He'nan
<120>a kind of polygenes recombinates Lactobacillus casei, preparation method and application
<160> 19
<170> SIPOSequenceListing 1.0
<210> 1
<211> 21
<212> DNA
<213>artificial sequence
<400> 1
atgttggtaa cacctctttt a 21
<210> 2
<211> 21
<212> DNA
<213>artificial sequence
<400> 2
tctaaaacga cgtgttccat t 21
<210> 3
<211> 23
<212> DNA
<213>artificial sequence
<400> 3
tgctttcatt aaaagaaaaa gta 23
<210> 4
<211> 24
<212> DNA
<213>artificial sequence
<400> 4
atttaggaaa tcggtcatta tgcc 24
<210> 5
<211> 24
<212> DNA
<213>artificial sequence
<400> 5
atgaaaaaat tgcttttaac aact 24
<210> 6
<211> 24
<212> DNA
<213>artificial sequence
<400> 6
ttattcgtat gcgatagtat agtt 24
<210> 7
<211> 54
<212> DNA
<213>artificial sequence
<400> 7
ggggatcgat cctctagagt cgaccatgtt ggtaacacct cttttactag tgac 54
<210> 8
<211> 42
<212> DNA
<213>artificial sequence
<400> 8
tactttttct tttaatgaaa gcattctaaa acgacgtgtt cc 42
<210> 9
<211> 42
<212> DNA
<213>artificial sequence
<400> 9
taatggaaca cgtcgtttta gaatgctttc attaaaagaa aa 42
<210> 10
<211> 44
<212> DNA
<213>artificial sequence
<400> 10
agttgttaaa agcaattttt tcatatttag gaaatcggtc atta 44
<210> 11
<211> 44
<212> DNA
<213>artificial sequence
<400> 11
ggcataatga ccgatttcct aaatatgaaa aaattgcttt taac 44
<210> 12
<211> 55
<212> DNA
<213>artificial sequence
<400> 12
ctccaaatat cgtagcgccg gggtacctta ttcgtatgcg atagtatagt tcacg 55
<210> 13
<211> 54
<212> DNA
<213>artificial sequence
<400> 13
ggggatcgat cctctagagt cgaccatgtt ggtaacacct cttttactag tgac 54
<210> 14
<211> 55
<212> DNA
<213>artificial sequence
<400> 14
ctccaaatat cgtagcgccg gggtacctta ttcgtatgcg atagtatagt tcacg 55
<210> 15
<211> 53
<212> DNA
<213>artificial sequence
<400> 15
actatactat cgcatacgaa taaggtaccc cggcgctacg atatttggag ttg 53
<210> 16
<211> 53
<212> DNA
<213>artificial sequence
<400> 16
actagtaaaa gaggtgttac caacatggtc gactctagag gatcgatccc cgg 53
<210> 17
<211> 20
<212> DNA
<213>artificial sequence
<400> 17
gcctcctcat cctcttcatc 20
<210> 18
<211> 20
<212> DNA
<213>artificial sequence
<400> 18
aatatcgtag cgccggggta 20
<210> 19
<211> 5061
<212> DNA
<213>artificial sequence
<400> 19
atgttggtaa cacctctttt actagtgact cttttgtgtg tactatgtag tgctgctttg 60
tatgacagta gttcttacgt ttactactac caaagtgcct ttagaccacc taatggttgg 120
catttacacg ggggtgctta tgcggtagtt aatattttta gcgaatctaa taatgcaggc 180
tcttcacctg ggtgtattgt tggtactatt catggtggtc gtgttgttaa tgcttcttct 240
atagctatga cggcaccgtc atcaggtatg gctttgtcta gcagtcagtt ttgtactgca 300
cactgtaact tttcagatac tacagtgttt gttacacatt gttataaata tgatgggtgt 360
cctataactg gcatgcttca aaagaatttt ttacgtgttt ctgctatgaa aaatggccag 420
cttttctata atttaacagt tagtgtagct aagtacccta cttttaaatc atttcagtgt 480
gttaataatt taacatccgt atatttaaat ggtgatcttg tttacacctc taatgagacc 540
acagatgtta catctgcagg tgtttatttt aaagctggtg gacctataac ttataaagtt 600
atgagagaag ttaaagccct ggcttatttt gttaatggta ctgcacaaga tgttattttg 660
tgtgatggat cacctagagg cttgttagca tgccagtata atactggcaa tttttcagat 720
ggcttttatc cttttattaa tagtagttta gttaagcaga agtttattgt ctatcgtgaa 780
aatagtgtta atactacttt tacgttacac aatttcactt ttcataatga gactggcgcc 840
aaccctaatc ctagtggtgt tcagaatatt caaacttacc aaacacaaac agctcagagt 900
ggttattata attttaattt ttcctttctg agtagttttg tttataagga gtctaatttt 960
atgtatggat cttatcaccc aagttgtaat tttagactag aaactattaa taatggcttg 1020
tggtttaatt cactttcagt ttcaattgct tacggtcctc ttcaaggtgg ttgcaagcaa 1080
tctgtcttta gtggtagagc aacttgttgt tatgcttatt catatggagg tccttcgctg 1140
tgtaaaggtg tttattcagg tgagttagat cttaattttg aatgtggact gttagtttat 1200
gttactaaga gcggtggctc tcgtatacaa acagccactg aaccgccagt tataactcga 1260
cacaattata ataatattac tttaaatact tgtgttgatt ataatatata tggcagaact 1320
ggccaaggtt ttattactaa tgtaaccgac tcagctgtta gttataatta tctagcagac 1380
gcaggtttgg ctattttaga tacatctggt tccatagaca tctttgttgt acaaggtgaa 1440
tatggtctta cttattataa ggttaaccct tgcgaagatg tcaaccagca gtttgtagtt 1500
tctggtggta aattagtagg tattcttact tcacgtaatg agactggttc tcagcttctt 1560
gagaaccagt tttacattaa aatcactaat ggaacacgtc gttttagaat gctttcatta 1620
aaagaaaaag taactggaat agattttgat gcaatcaaag ataaagtcgt ttcattaaaa 1680
aacacggttt caaatattga ttttaatctg gttaaagaag atatttcttc tttaaaaagc 1740
aatgcgttat ccatcgcggc atcagatttt aaaaataaac cggtgttatt caaagactct 1800
ttagacttac ttactgatgc tacaaataca ctcagaaaga ttaccaatca aatgtcatca 1860
attagcgaaa tttctaataa gtcattagat ttgctggatt ctctttttga ggctgccaaa 1920
gatattgtaa acattgccta ttcaaaaggt ggtgtcgaaa ttactaagtc tgcgacagaa 1980
ttagcggcaa aagcggcatt aattgttgat aaaagtatca tattagcaaa taaagataat 2040
acaattagtg aagctgttta tcattctatt aacaactcat tacaaaatat tcaaaaaaca 2100
gctatcaata ttgctacaca ttcacataat gaagataaag ctgaaattgc taaagcctct 2160
tttgagctgt tatctcaagt tagtgatgtt atcagtaatg cgttaaaaaa ttcaggtgat 2220
ataggtatcg aatcacaact cttagccgat attaatcagt tttctcattc tattttgaac 2280
acagctaaaa cagttactga tatagctact atggatatga atgataaaac ctcaatcgct 2340
aaaaatagca tttcattaat agccaaagtg aatgatgtta tttccgatat tctagtaatg 2400
acggataaag acaccgaatt attaaatgca attcataatg ttactgcgaa aaatctacag 2460
aatatcgaag agagtgcggt caatcttgca aatgctgatg tgctgtctca agaaggcaaa 2520
gtcagtattg ccattaattc tttaacttta atatcacaaa ccaacaaaat tgttgcgcaa 2580
gtgctaaatg aagctaattt aagcactgat aaaacccaat ttgttggcga attaaccgat 2640
gtattattga ataccgcaaa aagtattaca ttgttagcta ccggtaataa tgcgacaaca 2700
gcaggaaagg aacagctggc agttgcctca accaatctta ttggtaacgt gaatgatctc 2760
attcaatcaa ttaccagctt taaaggcaaa gaagatattg gtaacgcttt acacagtgcg 2820
gtggacggac aattatcaca aatcaaacaa cttgcggtcg cgttatcaaa cagtaatctt 2880
gattcttcac aaggtaaaac tgcaatagcc atcacctctt tcggcttgat tgcacaagca 2940
aataatatta tcaataaatt cttggataat atgagtttaa gtactaatgt gagtaaatcg 3000
gttcatagtt tgactaattc agcgctagat gcagccaaaa ttctcacaaa cgtagtacaa 3060
gtagatgcta ataacaatca aggaaaggtc gtgattgcca atagttcatt agaactttct 3120
aaaacagcaa gtgatattgt gtctactgtg ttaaaaagca catctatttc aacacaacat 3180
attgatataa ttcataatgc agtaaataaa acattaacag aaatgaaaga tagtgcggta 3240
gcaatagcac ttgcttcatc tgaaaataat agcgctgaaa ttgcaacgca ttcattaagt 3300
ctgttatccg atgcaagtaa tatgttgaaa gatattatgc aaggaatgag ccctaataat 3360
gtcattgctc cgaaaacatt agaattattt aactcactat ttgcgacagc tcaaaatatc 3420
gttcaattag ctgacgcaaa atcttcagaa aacattgcta aagctagtgt tgatttggta 3480
caaagcgcaa cgattatcct caataacgta ttaacgttgg ctaacgttga ttcttcttta 3540
agtaaagctt ttcatcaatc atttgatgct tcagtttctc aaattaaaga ggtagcagct 3600
caattagcta ccgcgtcttc tgcctctaat aaagctgaga ttgcaaaact ctcttttgat 3660
tttattagtc aagtaagtga tttagcgacc aacaccttaa caacagcgaa aaccggatta 3720
gatagcacgc tgctgaataa cgttaacggt ctttctcatt ccgtcttaaa tgcagcaaaa 3780
tcagtaaccg atattattgt gagtgataac ccagcgaata ccgccagttt atccgtttct 3840
ttggtgaata atgccaatga aattgtttca aatatcttaa ccttatccgg aaaacaaaat 3900
acgctctcca cggcagtaca cgatataacc gctaaacatt tagcgccgat tgagaaaata 3960
gcaattaacc ttgcgaatgc cgataactca agcagtgatg gaaaagttgc tattgcgtta 4020
aactcattaa cattgattgc acaaagtaac catttaatcg aagaagtatt aaaagaggct 4080
aaattagata atgcgaagag cgcctttgct cacaatttaa cggatttagt attagatacc 4140
gccaaaacaa tcacggcatt agcatcagcg gataccagta aagtagacgg caagcagcag 4200
attgcctctg catcaacaca tttagtcgga caaattaatg agattgtcaa atcaatcacg 4260
acaataacca attcagaaac gaaagtcggc aatgccgcat atcaagcgtt aaaaacacat 4320
ttagagcagg tagaaacaat tgcggttaaa cttgccgccg ccaatgcatc aacagcggaa 4380
ggcagaacag aaattgcgat tgaatctttc aatttaatcg caaaaaccaa tggcataatg 4440
accgatttcc taaatatgaa aaaattgctt ttaacaactt taattgccgt tggtttgggc 4500
ttatcagcac aaggtgcatt tgcggatgat cctagtgcag ctaattcaac aaatggcggt 4560
cttattacaa tcactggtaa agtaacagat accacttgtt taattaatgg aaaagaaaat 4620
ggcgatttga cagtacaatt accaccagtt tctacaaaag cgctagctac tcagggcgca 4680
acaacaggtg atacagcatt tacaattgaa ttaagtggtt gtcaatctgc aacagataaa 4740
cttgcaaaaa aagcagcagc attcttcgtg aatgaatcag ataaagtaac agctgatggt 4800
aagttactaa ataaacctgc aactcctggt gatgcagctc aaaatgtggt ggtgcaatta 4860
cttcacggtg atgatactcc aattgatatt acaaaacctt atgcggaaca aactaaagag 4920
gctcaaaaag ctggaattga ttcaagcaag aaaacagcca cattgaaata taaagctcgt 4980
tactatgcaa ctaatccggc aggagcgggt gaggtgaaat ctaccgtgaa ctatactatc 5040
gcatacgaat aaggtacccc g 5061
Claims (4)
1. a kind of polygenes recombinates Lactobacillus casei, which is characterized in that the polygenes recombination Lactobacillus casei is by recombinating
Plasmid pMG36e-S1-GtxA-flfA electrotransformation to cheese lactic acid competent cell bacillus obtains;The recombinant plasmid pMG36e-
S1-GtxA-flfA be fusion S1-GtxA-flfA is connected into linear plasmid pMG36e the site kPnI and the site SalI it
Between obtain, the nucleotide sequence of the fusion S1-GtxA-flfA is as shown in SEQ ID NO.19.
2. a kind of polygenes as described in claim 1 recombinates Lactobacillus casei, which is characterized in that the Lactobacillus casei
For Lb.caseiCECT5276.
3. the preparation method of polygenes recombination Lactobacillus casei as described in claim 1, which is characterized in that including following step
It is rapid:
S1 designs specificity amplification primer 1, upstream and downstream primer such as sequence table SEQ using IBV Jin-13 virus cDNA as template
Shown in ID NO:1 and SEQ ID NO:2, carries out PCR amplification and obtain IBV virus S1 genetic fragment;Amplified fragments after glue recycles with
PMD18-T carrier is attached, and connection product is converted to bacillus coli DH 5 alpha competent cell, obtains recombinant plasmid pMD18-
T-S1;
Using G.anatis full-length genome as template, specificity amplification primer 2, upstream and downstream primer such as sequence table SEQ ID are designed
Shown in NO:3 and SEQ ID NO:4, carries out PCR amplification and obtain G.anatis GtxA genetic fragment;Amplified fragments after glue recycles with
PMD18-T carrier is attached, and connection product is converted to bacillus coli DH 5 alpha competent cell, obtains recombinant plasmid pMD18-
T-GtxA;
Using G.anatis full-length genome as template, specificity amplification primer 3, upstream and downstream primer such as sequence table SEQ ID are designed
Shown in NO:5 and SEQ ID NO:6, carry out PCR amplification and obtain G.anatis flfA genetic fragment, amplified fragments after glue recycles with
PMD18-T carrier is attached, and connection product is converted to bacillus coli DH 5 alpha competent cell, obtains recombinant plasmid pMD18-
T-flfA。
S2 designs specificity amplification primer 4, upstream and downstream primer such as sequence table SEQ ID with recombinant plasmid pMD18-T-S1 template
Shown in NO:7 and SEQ ID NO:8, PCR amplification is carried out, identified result correctly carries out glue recycling afterwards, obtains target fragment 1;
With recombinant plasmid pMD18-T-GtxA template, specificity amplification primer 5, upstream and downstream primer such as sequence table SEQ ID are designed
Shown in NO:9 and SEQ ID NO:10, PCR amplification is carried out, it is identified, glue recycling is carried out after as a result correct, obtains target fragment 2;
With recombinant plasmid pMD18-T-flf template, specificity amplification primer 6, upstream and downstream primer such as sequence table SEQ ID are designed
Shown in NO:11 and SEQ ID NO:12, PCR amplification is carried out, identified result correctly carries out glue recycling afterwards, obtains target fragment 3;
S3 is once expanded target fragment 1, target fragment 2 and target fragment 3 by overlapping PCR method, primary to expand
Specificity amplification primer 7, upstream and downstream primer such as sequence table SEQ ID NO:13 and SEQ are added into PCR system after terminating for increasing
Shown in ID NO:14, secondary amplification is carried out, correct amplified production recycling will be identified, obtains fusion S1-GtxA-flfA;
S4 designs specificity amplification primer 8, upstream and downstream primer such as sequence table SEQ ID NO:15 using pMG36e plasmid as template
With shown in SEQ ID NO:16, PCR amplification is carried out, obtains linear plasmid pMG36e;
Fusion S1-GtxA-flfA and linear plasmid pMG36e are attached by seamless clone technology, will be connected by S5
Product is converted to Escherichia coli XL1-Bule competent cell, obtains recombinant plasmid pMG36e-S1-GtxA-flfA;
S6 mixes recombinant plasmid pMG36e-S1-GtxA-flfA with Lactobacillus casei competent cell, ice bath 5min, so
High-voltage pulse electric shock converts afterwards, much genetic recombination Lactobacillus casei.
4. the preparation method of polygenes recombination Lactobacillus casei as claimed in claim 3, which is characterized in that in S1, PCR body
System are as follows: 2 × Easy Taq Super PCR Master Mix 25ul, upstream primer 1ul, downstream primer 1ul, template
DNA21ul;
PCR program are as follows:
95 DEG C, 5min;
30 circulations:
95 DEG C, 30s,
56 DEG C, 30s,
72 DEG C, primer 1 expands 60s/ primer 2 amplification 90s/ primer 3 and expands 30s;
72℃,10min。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910668557.5A CN110358782A (en) | 2019-07-23 | 2019-07-23 | A kind of polygenes recombination Lactobacillus casei, preparation method and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910668557.5A CN110358782A (en) | 2019-07-23 | 2019-07-23 | A kind of polygenes recombination Lactobacillus casei, preparation method and application |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110358782A true CN110358782A (en) | 2019-10-22 |
Family
ID=68219878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910668557.5A Pending CN110358782A (en) | 2019-07-23 | 2019-07-23 | A kind of polygenes recombination Lactobacillus casei, preparation method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110358782A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160106828A1 (en) * | 2014-10-20 | 2016-04-21 | Auburn University | Adaptation of attenuated infectious bronchitis virus (ibv) to embryonic kidney cells and vaccine thereby produced |
TWI614026B (en) * | 2016-10-25 | 2018-02-11 | 國立中興大學 | Recombinant avibacterium paragallinarum flfa fimbrium subunit vaccine for infectious coryza of chickens, preparation method and use thereof |
CN108653724A (en) * | 2017-04-01 | 2018-10-16 | 普莱柯生物工程股份有限公司 | It is a kind of for prevent fowl egg drop syndrome vaccine composition, and its preparation method and application |
-
2019
- 2019-07-23 CN CN201910668557.5A patent/CN110358782A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160106828A1 (en) * | 2014-10-20 | 2016-04-21 | Auburn University | Adaptation of attenuated infectious bronchitis virus (ibv) to embryonic kidney cells and vaccine thereby produced |
TWI614026B (en) * | 2016-10-25 | 2018-02-11 | 國立中興大學 | Recombinant avibacterium paragallinarum flfa fimbrium subunit vaccine for infectious coryza of chickens, preparation method and use thereof |
CN108653724A (en) * | 2017-04-01 | 2018-10-16 | 普莱柯生物工程股份有限公司 | It is a kind of for prevent fowl egg drop syndrome vaccine composition, and its preparation method and application |
Non-Patent Citations (3)
Title |
---|
JOHNSON,T.J.等: "Complete Genome Sequence of Gallibacterium anatis Strain UMN179,Isolated from a Laying Hen with Peritonitis", 《NCBI GENBANK》 * |
PEDERSEN I.J等: "Immunogenic and protective efficacy of recombinant protein GtxA-N against Gallibacterium anatis challenge in chickens", 《AVIAN PATHOLOGY》 * |
刘慧敏等: "输卵管囊肿病鸡的病理学观察及相关病原的初步检测", 《第十三次学术研讨会会议论文集》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0431668A1 (en) | Recombinant herpesvirus of turkeys and live vector vaccines derived thereof | |
CN105420261B (en) | A kind of heat-resisting remodeling method of newcastle disease virus and application | |
CN109321534A (en) | A kind of recombination VIII type newcastle disease virus low virulent strain | |
CN112625095B (en) | Porcine rotavirus recombinant protein, recombinant adenovirus expressing protein and application of recombinant adenovirus | |
CN106554944A (en) | The vaccine combination and application of pig epidemic diarrhea virus attenuated strain and its preparation | |
CN107099496A (en) | Recombinant strains of lactic acid bacteria of amalgamation and expression infections chicken cloacal bursa virus VP2 albumen and Salmonella outer membrane protein and application thereof | |
CN109266593A (en) | Based on Ngpiwi protein mediated eggs crack detection gene knock-out bacterial strain and its construction method and application | |
CN110124025A (en) | A kind of bird flu and 4 type bigeminy genetic engineering subunit vaccine of aviadenovirus and preparation method thereof | |
CN112159479B (en) | Mycoplasma gallisepticum multi-antigen epitope fusion protein pMG-mEA and application thereof | |
CN110205308A (en) | It is a kind of express HA gene recombinant herpesvirus of turkeys and its application | |
CN117838890A (en) | C-type avibacterium paragallinarum subunit vaccine and application thereof | |
CN110016457B (en) | Rough brucella abortus for recombining echinococcus granulosus Eg95gene and vaccine production method thereof | |
CN110358782A (en) | A kind of polygenes recombination Lactobacillus casei, preparation method and application | |
CN114807223B (en) | Construction method of porcine epidemic diarrhea virus infectious clone | |
CN114854783B (en) | Recombinant lactococcus lactis expressing epidemic strain S1 of PEDV as well as preparation method and application thereof | |
CN110128545A (en) | A kind of fusion, recombinant expression carrier, antigen and its preparation method and application | |
CN109867713A (en) | A kind of canine distemper genetic engineering subunit vaccine | |
CN116042540A (en) | Separation and application of cat rhinotracheitis virus FHV-1WH-2017 strain | |
CN111647610B (en) | H9N2 subtype avian influenza virus with exchanged HA and NS1 deletion gene packaging signals and construction method and application thereof | |
CN106754984A (en) | Expression Porcine epidemic diarrhea virus S318The Recombinant Lactococcus lactis of gene and application | |
CN104762244B (en) | Streptococcus suis SBP_bac_5 gene-deleted strains and its construction method and application | |
CN108690834B (en) | Raccoon parvovirus strain and application thereof, raccoon parvovirus inactivated vaccine and preparation method thereof | |
CN109735510B (en) | Porcine pseudorabies virus variant HN-QYY, HN-QYY-gE-and construction method and application thereof | |
CN106834310A (en) | Expression pig infectious gastroenteritis virus S600The Recombinant Lactococcus lactis of gene and application | |
CN109608535A (en) | A kind of the chicken alpha interferon peptide chain and its recombinant expression engineered strain of optimization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191022 |
|
RJ01 | Rejection of invention patent application after publication |